Enlivex Therapeutics Ltd. (ENLV) Financials

ENLV Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 4.9 billion 1.0 billion
March 31, 2026 ? ?
Dec. 31, 2025 2.3 billion 392.1 million
Sept. 30, 2025 20.9 million 3.5 million

ENLV Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -5.5 million ?
March 31, 2026 -5.5 million ?
Dec. 31, 2025 -2.9 million 915000
Sept. 30, 2025 -2.3 million 280000

ENLV Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
June 30, 2026 1.9 billion
March 31, 2026 974.5 million
Dec. 31, 2025 1.2 billion
Sept. 30, 2025 -2.2 million

ENLV Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 5.5 million - 371000
March 31, 2026 - - -
Dec. 31, 2025 5.9 million - 641000
Sept. 30, 2025 18.3 million - 701000

ENLV Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 19.3 million
March 31, 2026 18.0 million
Dec. 31, 2025 3.2 million
Sept. 30, 2025 1.6 million

ENLV Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 4500 2.9 million 1.3 million -
March 31, 2026 4500 3.3 million 4.6 million -
Dec. 31, 2025 9383 3.0 million 2.7 million -
Sept. 30, 2025 23554 1.5 million 1.1 million -

ENLV Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - 57000
March 31, 2026 - -
Dec. 31, 2025 - 76000
Sept. 30, 2025 - 81000

ENLV

Price: $1.44

52 week price:
1.40
434.40

Earnings Per Share: 415.39 USD

P/E Ratio: 0.00

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: Israel

Volume: 21300

Market Capitalization: 23.7 million

Links: